PROVENANCE

Provenance Group, an Alternative Protein Startup, Receives National Institutes of Health (NIH) SBIR Phase I Research Grant
San Francisco, CA
September 22, 2021
For Immediate Release

- Provenance Group has been awarded a SBIR Phase 1 research grant by the National Institute of General Medical Sciences of the National Institutes of Health.
- The grant will further the company's research in the creation of functional collagens specifically for applications in tissue engineering and biomaterials.

San Francisco, September 22, 2021 - Provenance Group, the operating company for San Francisco-based alternative proteins company, Provenance Bio, announced today that it has been awarded a SBIR Phase 1 research grant by the National Institute of General Medical Sciences of the National Institutes of Health.

The grant will further the company's research in the creation of functional collagens specifically for applications in tissue engineering and biomaterials.

"Today I am proud to announce that a branch of Provenance research has received funding from the NIH to advance the availability of a new class of protein building blocks," says Michalyn Andrews, Provenance Group CEO.

Collagens are the most abundant protein in the human body, the primary protein component of the extracellular matrix, and the main structural component of connective tissues. Because of this ubiquitous nature, consumer applications include those from the therapeutics and biomedical industries to foods and pharmaceutical drug delivery systems.

"Harnessing functional collagens opens up not only the opportunity to advance the circular economy and build products we consume more sustainably, but also to open up possibilities for biomedical applications that have been previously inaccessible due to lack of biocompatible proteins in large quantities," continues Andrews.

As part of its NIH research, Provenance aims to make collagen proteins with total precision and high efficiency.

"We are excited to be addressing the challenges of making functional proteins at high efficiencies via cutting edge systems and are aligned with the NIH's mission of enhancing health, lengthening life, and reducing illness as part of our overall goal of advancing a sustainable future," continues Andrews.

Research referenced in this release is supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R43GM144011. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

--
About Provenance

Provenance is an alternative proteins company developing cutting edge synthetic biology tools to compete head-to-head with animal proteins, today leveraging its patent-pending platform to make full-length collagen for B-to-B applications in pharma, biomaterials, therapeutics, and food. The Provenance protein expression platform represents the future of biomanufacturing, efficiently making the protein building blocks needed to usher in a new era of sustainable products.

Provenance was formed in 2020, co-founded by Michalyn Andrews, Dr. Zev Gartner, Dr. John Dueber, and Christian Ewton.

For further information: visit http://provenance.bio or email info@provenance.bio.

Press Contact
press@provenance.bio